$IGMS News
Last published 1y ago
- 1y agoIGMSIGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value RightGlobeNewswireMOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it
- 1y agoIGMSIGM Biosciences Provides Strategic Update on Autoimmunity Pipeline ProgramsGlobeNewswire– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 –
- 2y agoIGMSIGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for
- 2y agoIGMSIGM Biosciences to Present at Three Upcoming Investor ConferencesGlobeNewswireMOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management
- 2y agoIGMSIGM Biosciences Announces Strategic Pivot to Focus Exclusively on AutoimmunityGlobeNewswire– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D.,
- 2y agoIGMSIGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation SummitGlobeNewswireMOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred
- 2y agoIGMSIGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis clinical trial –
- 2y agoIGMSIGM Biosciences to Present at the Jefferies Healthcare ConferenceGlobeNewswireMOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred
- 2y agoIGMSIGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08,
- 2y agoIGMSIGM Biosciences to Present at the 2024 RBCCM Global Healthcare ConferenceGlobeNewswireMOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management
- 2y agoIGMSIGM Biosciences Announces Refocusing of Sanofi CollaborationGlobeNewswireMOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the
- 2y agoIGMSIGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology ForumGlobeNewswireMOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred
- 2y agoIGMSIGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswireMOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial
- 2y agoIGMSIGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewswireMOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred
- 2y agoIGMSIGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireMOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred
- 2y agoMVIRIGMSMedivir to present at the Carlsquare Equity Research Investor DayPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoIGMSIGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway ExtensionGlobeNewswire– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All clinical development
- 2y agoIGMSBulletin from Extraordinary General Meeting in Medivir AB (publ)PR NewswireToday on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below was...
- 2y agoMVIRIGMSMedivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCCPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRIGMSMedivir to present at the Redeye Life Science DayPR NewswireMedivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRIGMSMedivir to present at the Erik Penser Bank Company EventPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoIGMSIGM Biosciences Announces Third Quarter 2023 Financial ResultsGlobeNewswire– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc.
- 2y agoMVIRIGMSMedivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDAPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 3y agoIGMSIGM Biosciences to Present at Two Upcoming Investor ConferencesGlobeNewswireMOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that
- 3y agoMVIRIGMSMedivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on FridayPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 3y agoMVIRIGMSNomination Committee of Medivir appointedPR NewswireMedivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May...
- 3y agoMVIRIGMSChange in Medivir's Board of DirectorsPR NewswireMedivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...
- 3y agoIGMSMVIRFostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cyclesPR NewswireEarly and confirmed anti-tumor activity, 16 of 20 patients with disease control at first scan and sustained tumor control for 13 of 18 patients with >3 months follow-upDurable clinical benefit, median time to
- 3y agoIGMSIGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of DirectorsGlobeNewswireMOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that
- 3y agoIGMSMVIRMedivir to present at the Pareto Securities Healthcare ConferencePR NewswireSTOCKHOLM, Sweden , Sept. 14, 2023 /PRNewswire/ -- Medivir AB (NASDAQ:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical
- 3y agoIGMSMedivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical studyPR NewswireSTOCKHOLM, Sept. 11, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that
- 3y agoIGMSMedivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCAPR NewswireSTOCKHOLM, Sept. 7, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical needs, today announces that data on
- 3y agoIGMSIGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewswireMOUNTAIN VIEW, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that
- 3y agoIGMSMedivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with LenvimaPR NewswireCentral review of the 6 patients in phase 1b dose escalation part was performedIn these 6 patients, complete response was recorded in 1 patient, partial response in 2 patients, and stable disease in 2 patients read by an
- 3y agoIGMSMedivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCCPR NewswireSTOCKHOLM, Sept. 1, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that it
- 3y agoIGMSMedivir to present at the Erik Penser Bank Company EventPR NewswireSTOCKHOLM, Aug. 23, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the
- 3y agoIGMSMVIRPromising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient includedPR NewswireContinued tumor control in the liver in 7 of the first 10 patients after three months of treatmentThe patient who benefited the longest from fostrox + Lenvima® remains on treatment after 12 months, with tumor
- 3y agoIGMSMVIRMedivir partners with world-leading liver cancer experts in new Scientific Advisory CouncilPR NewswireSTOCKHOLM, Aug. 7, 2023 /PRNewswire/ -- Medivir AB (NASDAQ:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the
- 3y agoIGMSIGM Biosciences Announces Second Quarter 2023 Financial ResultsGlobeNewswire– Continued progress in clinical development across portfolio –– Public equity offering and concurrent private placement with gross proceeds of $120.0 million – MOUNTAIN VIEW, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) --
- 3y agoIGMSIGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewswireMOUNTAIN VIEW, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS) today announced the closing of its previously announced upsized underwritten public offering of 1,597,827 shares of its
- 3y agoIGMSIGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private PlacementGlobeNewswireMOUNTAIN VIEW, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS) today announced the pricing of its upsized underwritten public offering of 3,285,327 shares of its voting common stock and
- 3y agoIGMSIGM Announces Proposed Public Offering and Concurrent Private PlacementGlobeNewswireMOUNTAIN VIEW, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS) today announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common stock and, in lieu
- 3y agoIGMSMVRBFMedivir's patent application for fostrox approved in ChinaPR NewswireSTOCKHOLM, June 19, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that the
- 3y agoIGMSIGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical DevelopmentGlobeNewswire– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients – – Progression-free survival of 5.6 months in median
- 3y agoIGMSMedivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and LenvimaPR NewswireSTOCKHOLM, June 2, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that a
- 3y agoIGMSIGM Biosciences to Present at the Jefferies Healthcare ConferenceGlobeNewswireMOUNTAIN VIEW, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that
- 3y agoIGMSMedivir to present at the Redeye Growth DayPR NewswireSTOCKHOLM, June 1, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company
- 3y agoIGMSIGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid ArthritisGlobeNewswireMOUNTAIN VIEW, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that the U.S. Food
- 3y agoIGMSChange in the number of shares and votes in Medivir AB (publ)PR NewswireSTOCKHOLM, May 31, 2023 /PRNewswire/ -- Medivir AB (publ) ("Medivir") (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May 2023 as a result of the
- 3y agoIGMSIGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical UpdateGlobeNewswire– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on